University of Cambridge > > Cambridge Biomedical Research Centre "Distinguished Visitors" 2017 Lecture Series > Realizing a new paradigm in human genetics guided drug discovery

Realizing a new paradigm in human genetics guided drug discovery

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Sylvie Robinson.

Book your free ticket on

Nadeem’s expertise stems from the intersection of innovation in human genetics and data sciences with collaborative business models to accelerate delivery of novel, targeted therapeutics. He is Founder and President of the Eisai AiM Institute, an industry unique discovery innovation unit exclusively focused on realizing human genetics guided drug discovery and precision medicine. He has senior-level experience within academia (tenured faculty, University of Cambridge), big-pharma (Senior Director, Pfizer), medium-sized pharma (Vice President, Eisai), and Biotech-like organizations (President, Eisai AiM Institute). Nadeem’s research has been published in leading medical journals (eg, NEJM , Lancet, JAMA ), presented at international meetings (eg, American Diabetes Association, Prix Galien Foundation, Hitachi Innovation), and profiled by international media (eg, BBC , Forbes, Nature). He has been invited to provide expert insights on human genetics and drug discovery for The World Dementia Envoy, Genomics England, The UK Minster for Life Sciences and Scottish Enterprise. Nadeem has served as Chair of: The US National Academies Workshop on “Drug Discovery From Genetic Bioresources”; The World CNS Summit; The Drug Discovery Stream of the Festival of Genomics; and The External Advisory Board of the NIA Longevity Genomics Study. In addition, he serves as industry lead for the ADNI Genetics Core; sits on the US Institute of Medicine Roundtable on Genomics & Precision Health; and facilitates the Industry Partnership for Human Genetics. Prior to working in the pharmaceutical industry, Nadeem was tenured faculty at the School of Clinical Medicine, University of Cambridge (UK), where he was involved in leading large-scale research consortia and new bioresources focused on identifying causal and predictive disease risk factors. He served as Principal Investigator of the IL6R Genetics Consortium and the Triglycerides & Coronary Disease Genetics Consortium; and Steering Committee & Leadership Team member of the Emerging Risk Factors Collaboration, the Pakistan Risk of Myocardial Infarction Study and Generation Scotland. He trained in genetic and molecular epidemiology with Professor John Danesh (University of Cambridge, UK).

This talk is part of the Cambridge Biomedical Research Centre "Distinguished Visitors" 2017 Lecture Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity